Tactile Systems Technology, Inc. (TCMD)
NASDAQ: TCMD · Real-Time Price · USD
23.70
-0.67 (-2.75%)
At close: Nov 14, 2025, 4:00 PM EST
23.71
+0.01 (0.04%)
After-hours: Nov 14, 2025, 5:33 PM EST
TCMD Revenue
Tactile Systems Technology had revenue of $85.76M in the quarter ending September 30, 2025, with 17.32% growth. This brings the company's revenue in the last twelve months to $311.51M, up 9.28% year-over-year. In the year 2024, Tactile Systems Technology had annual revenue of $292.98M with 6.76% growth.
Revenue (ttm)
$311.51M
Revenue Growth
+9.28%
P/S Ratio
1.77
Revenue / Employee
$300,398
Employees
1,037
Market Cap
529.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 292.98M | 18.56M | 6.76% |
| Dec 31, 2023 | 274.42M | 27.64M | 11.20% |
| Dec 31, 2022 | 246.79M | 38.73M | 18.61% |
| Dec 31, 2021 | 208.06M | 20.93M | 11.18% |
| Dec 31, 2020 | 187.13M | -2.36M | -1.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TCMD News
- 11 days ago - Tactile Systems Technology Analysts Increase Their Forecasts After Better-Than-Expected Q3 Earnings - Benzinga
- 11 days ago - Tactile Systems Technology, Inc. (TCMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Tactile Systems Technology, Inc. Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 18 days ago - Landmark Study Demonstrates Sustained Clinical Benefits of Flexitouch® Plus as First-Line Therapy in Treating Head and Neck Cancer-Related Lymphedema - GlobeNewsWire
- 26 days ago - Tactile Medical to Release Third Quarter of Fiscal Year 2025 Financial Results on November 3, 2025 - GlobeNewsWire
- 3 months ago - Tactile Systems Technology, Inc. (TCMD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Tactile Systems Technology, Inc. Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Tactile Medical to Release Second Quarter of Fiscal Year 2025 Financial Results on August 4, 2025 - GlobeNewsWire